NDAORALTABLETPriority Review
Approved
Feb 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
Cytochrome P450 2C19 Inhibitors
Pharmacologic Class:
Anthelmintic
Indications (2)
Clinical Trials (1)
Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).
Started Feb 2022
301 enrolled
Fascioliasis